Page Limit Blunder Blocks Janssen’s Bid To Bar Amgen’s Ustekinumab
US District Court Pulls Up Janssen For Seven Minute Warning To Its Request
Janssen was pulled up for paperwork chicanery as it looked to obtain an early preliminary injunction against Amgen’s proposed biosimilar to its Stelara (ustekinumab).
You may also be interested in...
Fresenius Kabi insists there is a “business plan behind everything” as it divulged a higher cost savings goal for the end of next year, following a fruitful 2023. But queries over margins led the company to stress that it was combatting a variety of uncertainties, especially in China and for its burgeoning biosimilars unit.
In a much watched and controversial case that may have significant ramifications on the “chilling effects” of generics manufacturers in Israel being deterred from chasing after approvals in which an originator has deceitfully sought to ‘evergreen’ its branded intellectual property, the Israeli Supreme Court has once again come down on the side of the generics industry.
Samsung Bioepis is among a small pool of players heading to the clinic for a proposed biosimilar to Merck & Co’s PD-1 mega-blockbuster, as interest and investment rises ahead of patent expiry at the end of the decade.